CONTEXT: The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort represents the largest and best-characterized national sample of American youth with recent-onset type 2 diabetes. OBJECTIVE: The objective of the study was to describe the baseline characteristics of participants in the TODAY randomized clinical trial. DESIGN:Participants were recruited over 4 yr at 15 clinical centers in the United States (n = 704) and enrolled, randomized, treated, and followed up 2-6 yr. SETTING: The study was conducted at pediatric diabetes care clinics and practices. PARTICIPANTS: Eligible participants were aged 10-17 yr inclusive, diagnosed with type 2 diabetes for less than 2 yr and had a body mass index at the 85th percentile or greater. INTERVENTIONS: After baseline data collection, participants were randomized to one of the following groups: 1) metformin alone, 2) metformin plus rosiglitazone, or 3) metformin plus a lifestyle program of weight management. MAIN OUTCOME MEASURES: Baseline data presented include demographics, clinical/medical history, biochemical measurements, and clinical and biochemical abnormalities. RESULTS:At baseline the cohort included the following: 64.9% were female; mean age was 14.0 yr; mean diabetes duration was 7.8 months; mean body mass index Z-score was 2.15; 89.4% had a family history of diabetes; 41.1% were Hispanic, 31.5% were non-Hispanic black; 38.8% were living with both biological parents; 41.5% had a household annual income of less than $25,000; 26.3% had a highest education level of parent/guardian less than a high school degree; 26.3% had a blood pressure at the 90th percentile or greater; 13.6% had a blood pressure at the 95th percentile or greater; 13.0% had microalbuminuria; 79.8% had a low high-density lipoprotein level; and 10.2% had high triglycerides. CONCLUSIONS: The TODAY cohort is predominantly from racial/ethnic minority groups, with low socioeconomic status and a family history of diabetes. Clinical and biochemical abnormalities and comorbidities are prevalent within 2 yr of diagnosis. These findings contribute greatly to our understanding of American youth with type 2 diabetes.
RCT Entities:
CONTEXT: The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort represents the largest and best-characterized national sample of American youth with recent-onset type 2 diabetes. OBJECTIVE: The objective of the study was to describe the baseline characteristics of participants in the TODAY randomized clinical trial. DESIGN:Participants were recruited over 4 yr at 15 clinical centers in the United States (n = 704) and enrolled, randomized, treated, and followed up 2-6 yr. SETTING: The study was conducted at pediatric diabetes care clinics and practices. PARTICIPANTS: Eligible participants were aged 10-17 yr inclusive, diagnosed with type 2 diabetes for less than 2 yr and had a body mass index at the 85th percentile or greater. INTERVENTIONS: After baseline data collection, participants were randomized to one of the following groups: 1) metformin alone, 2) metformin plus rosiglitazone, or 3) metformin plus a lifestyle program of weight management. MAIN OUTCOME MEASURES: Baseline data presented include demographics, clinical/medical history, biochemical measurements, and clinical and biochemical abnormalities. RESULTS: At baseline the cohort included the following: 64.9% were female; mean age was 14.0 yr; mean diabetes duration was 7.8 months; mean body mass index Z-score was 2.15; 89.4% had a family history of diabetes; 41.1% were Hispanic, 31.5% were non-Hispanic black; 38.8% were living with both biological parents; 41.5% had a household annual income of less than $25,000; 26.3% had a highest education level of parent/guardian less than a high school degree; 26.3% had a blood pressure at the 90th percentile or greater; 13.6% had a blood pressure at the 95th percentile or greater; 13.0% had microalbuminuria; 79.8% had a low high-density lipoprotein level; and 10.2% had high triglycerides. CONCLUSIONS: The TODAY cohort is predominantly from racial/ethnic minority groups, with low socioeconomic status and a family history of diabetes. Clinical and biochemical abnormalities and comorbidities are prevalent within 2 yr of diagnosis. These findings contribute greatly to our understanding of American youth with type 2 diabetes.
Authors: John E Oeltmann; Angela D Liese; Howard J Heinze; Cheryl L Addy; Elizabeth J Mayer-Davis Journal: Diabetes Care Date: 2003-09 Impact factor: 19.112
Authors: Georgeanna J Klingensmith; Laura Pyle; Silva Arslanian; Kenneth C Copeland; Leona Cuttler; Francine Kaufman; Lori Laffel; Santica Marcovina; Sherida E Tollefsen; Ruth S Weinstock; Barbara Linder Journal: Diabetes Care Date: 2010-06-02 Impact factor: 19.112
Authors: Allison C Sylvetsky; Radha Nandagopal; Tammy T Nguyen; Marisa R Abegg; Mahathi Nagarur; Paul Kaplowitz; Kristina I Rother Journal: World J Diabetes Date: 2015-12-25
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2013-12-18 Impact factor: 29.690
Authors: Silva Arslanian; Laure El Ghormli; Morey H Haymond; Christine L Chan; Steven D Chernausek; Rachelle G Gandica; Rose Gubitosi-Klug; Lynne L Levitsky; Maggie Siska; Steven M Willi Journal: Pediatr Diabetes Date: 2020-03-03 Impact factor: 4.866
Authors: Tessa L Crume; Richard F Hamman; Scott Isom; Jennifer Talton; Jasmin Divers; Elizabeth J Mayer-Davis; Victor W Zhong; Angela D Liese; Sharon Saydah; Debra A Standiford; Jean M Lawrence; Catherine Pihoker; Dana Dabelea Journal: Ann Epidemiol Date: 2016-08-10 Impact factor: 3.797
Authors: Silva Arslanian; Laure El Ghormli; Joon Young Kim; Fida Bacha; Christine Chan; Heba M Ismail; Lorraine E Levitt Katz; Lynne Levitsky; Jeanie B Tryggestad; Neil H White Journal: Diabetes Care Date: 2018-11-19 Impact factor: 19.112